AI-Powered Enrollment Engine Delivers 30-45% Uplift in Eligible Referrals, Cuts Site Pre-Screening Time by 70%

San Francisco, CA – February 10, 2026 – TrialWire, the AI-driven patient recruitment platform transforming clinical trial enrollment, will be at OCT West Coast this week at the Moscone Center in San Francisco, February 12-14, 2026.

As biotechs face mounting pressure to embed AI into enrollment strategies from day zero, TrialWire offers sponsors an infrastructure-grade solution designed to accelerate complex, late-stage oncology and CNS trials where every month of delay compounds both cost and competitive risk.

The Enrollment Crisis Driving AI Adoption

With approximately 80% of clinical trials delayed due to enrollment challenges and Phase III delays costing sponsors upward of $50,000 per day, the message from investors at JPM 2026 was clear: AI-first enrollment is no longer optional—it's a must-have.

How TrialWire Delivers Results

TrialWire's always-on AI engine continuously finds, matches, and pre-screens patients across digital channels and real-world data, dynamically identifying highly specific subpopulations by medical status, prior therapies, comorbidities, and disease stage.

Proven performance metrics include:

• 30-45% uplift in eligible referrals versus conventional outreach

• 70% reduction in manual pre-screening time at sites

• 98% open rates on SMS-led engagement with 90-second median response times

• Under 24-hour activation to start or rescue stalled studies

The platform integrates seamlessly with existing CRO and sponsor infrastructure, offering role-based access for sites, sponsors, and CROs on an enterprise-grade health cloud platform designed to meet stringent regulatory and IT security standards.

Solving Site-Level Enrollment Bottlenecks

Tufts CSDD data show that 37% of investigative sites under-enroll, 11% fail to enroll a single patient, and roughly half of activated sites miss enrollment targets without intervention. TrialWire addresses this by systematically routing higher-quality referrals while eliminating pre-screening bottlenecks.

"In oncology and CNS, where screen-fail rates are high and inclusion/exclusion criteria are tight, speed and precision can be the difference between hitting enrollment targets and facing a mid-trial reset," saidSusan Fitzpatrick-Napier CEO & Founder TrialWire. "We built TrialWire as infrastructure, not innovation—a platform that sits underneath development programs and delivers predictable enrollment from first-patient-in to database lock."

Meet TrialWire at OCT West Coast

TrialWire representatives will be available throughout the conference to discuss AI-first recruitment strategies for late-stage trials.

Book a Meeting: Visit www.trialwire.ai/contact or contact [team@trialwire.com] to schedule a one-on-one consultation during OCT West Coast.